Antisense agents combining strongly bound base-modified oligonucleotide and artificial nuclease
IPC분류정보
국가/구분
United States(US) Patent
등록
국제특허분류(IPC7판)
C07H-021/04
C07H-021/00
A61K-031/70
출원번호
UP-0742384
(2007-04-30)
등록번호
US-7786292
(2010-09-20)
발명자
/ 주소
Karelson, Mati
Saarma, Mart
Pilv, Mehis
출원인 / 주소
Baltic Technology Development, Ltd.
대리인 / 주소
Marshall, Gerstein & Borun LLP
인용정보
피인용 횟수 :
1인용 특허 :
199
초록▼
The present invention provides compounds having a chelating moiety and an oligonucleotide sequence wherein the oligonucleotide includes one or more modified nucleobases, such as hydroxynucleobases. The disclosed compounds are suitable for antisense therapy. The chelating moiety can be complexed to a
The present invention provides compounds having a chelating moiety and an oligonucleotide sequence wherein the oligonucleotide includes one or more modified nucleobases, such as hydroxynucleobases. The disclosed compounds are suitable for antisense therapy. The chelating moiety can be complexed to an ion of a lanthanide metal. These compounds are efficient translation inhibitors of nucleic acids and have increased binding affinity for target nucleic acids. The invention also includes compositions and methods of using these compositions as antisense therapy.
대표청구항▼
What is claimed is: 1. A compound comprising an oligonucleotide having from 5 to 150 nucleobases and a chelating moiety attached to the oligonucleotide, wherein at least 10% of said nucleobases are a modified nucleobase selected from the group consisting of: 5-mercaptocytosine, 5-mercaptouracil, 8-
What is claimed is: 1. A compound comprising an oligonucleotide having from 5 to 150 nucleobases and a chelating moiety attached to the oligonucleotide, wherein at least 10% of said nucleobases are a modified nucleobase selected from the group consisting of: 5-mercaptocytosine, 5-mercaptouracil, 8-mercaptoguanine, 8-mercaptoadenine, 5-hydroxycytosine, 5-hydroxyuracil, 8-hydroxyadenine and 8-hydroxyguanine. 2. The compound of claim 1, wherein the modified nucleobase is a hydroxynucleobase selected from the group consisting of 5-hydroxycytosine, 5-hydroxyuracil, 8-hydroxyadenine and 8-hydroxyguanine. 3. The compound of claim 1 comprising from 10 to 100 nucleobases. 4. The compound of claim 1 comprising from 10 to 50 nucleobases. 5. The compound of claim 1 comprising from 20 to 30 nucleobases. 6. The compound according to claim 1, wherein at least 2 of the nucleobases are hydroxynucleobases selected from the group consisting of 5-hydroxycytosine, 5-hydroxyuracil, 8-hydroxyadenine and 8-hydroxyguanine. 7. The compound according to claim 6, wherein from 10% to 20% of the nucleobases are the hydroxynucleobases. 8. The compound according to claim 1, wherein the chelating moiety has a formula: wherein R is the oligonucleotide. 9. The compound according to claim 1, wherein the chelating moiety has a formula: wherein R is the oligonucleotide; and wherein R3 are independently selected from the group consisting of hydrogen, C1-8 alkane, C2-8 alkene, C2-8 alkyne, acylC1-8alkane, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, C1-8alkylaryl, and C1-8alkylheteroaryl. 10. The compound according to claim 1, wherein the chelating moiety has a formula: wherein R is the oligonucleotide; and wherein R2 is selected from C1-8 alkyl, C2-8 alkene, C2-8 alkyne, aryl, heteroaryl, C1-8alkylaryl, C1-8alkylheteroaryl, and acylC1-8alkane. 11. The compound according to claim 1, wherein the chelating moiety has a formula: wherein R is the oligonucleotide; and wherein R1 are independently selected from the group consisting of hydrogen, C1-8 alkane, C2-8 alkene, C2-8 alkyne, acylC1-8alkane, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, C1-8alkylaryl, and C1-8alkylheteroaryl. 12. The compound of claim 11, wherein R1 are independently selected from hydrogen, —C(O)CF3 and —CH2Phenyl, and wherein Phenyl is substituted with H, OH, C(O)Oheterocycloalkyl, C(O)Oalkyl, or alkyl. 13. The compound according to claim 1, wherein the chelating moiety has a formula: wherein R is the oligonucleotide; and wherein R1 is selected from the group consisting of hydrogen, C1-8 alkane, C2-8 alkene, C2-8 alkyne, acylC1-8alkane, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, C1-8alkylaryl, and C1-8alkylheteroaryl. 14. The compound according to claim 1, wherein the chelating moiety has a formula: wherein R is the oligonucleotide. 15. The compound according to claim 1, wherein the chelating moiety has a formula: wherein R is the oligonucleotide; and wherein R3 are independently selected from the group consisting of hydrogen, C1-8 alkane, C2-8 alkene, C2-8 alkyne, acylC1-8alkane, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, C1-8alkylaryl, and C1-8alkylheteroaryl. 16. The compound according to claim 1, wherein the chelating moiety has a formula: wherein R is the oligonucleotide. 17. The compound of claim 1, further comprising an ion of a metal, wherein the metal is selected from the group consisting of lanthanum, cerium, praseodymium, neodymium, promethium, samarium, europium, gadolinium, terbium, dysprosium, holmium, erbium, thulium, ytterbium, and lutetium. 18. The compound of claim 17, wherein the metal is europium or lanthanum. 19. A composition comprising the compound according to claim 1 and a pharmaceutically acceptable carrier. 20. The composition of claim 19 further comprising a delivery vehicle. 21. The composition of claim 20, wherein the delivery vehicle comprises a liposome, wherein the compound is contained within the liposome. 22. A method of inhibiting translation of a target nucleic acid comprising contacting the target nucleic acid with a compound according to claim 1, or a composition according to claim 19, under conditions that permit hybridizing of the compound to the target nucleic acid, wherein the hybridized compound inhibits translation of the target nucleic acid. 23. The method of claim 22 wherein the target nucleic acid is in an organism. 24. The method of claim 23 wherein the contacting comprises administering to the organism a composition that comprises the compound and a pharmaceutically acceptable carrier. 25. The method of claim 23, wherein the organism is a human or animal subject. 26. The method of claim 23, wherein the contacting comprises mixing the compound with a biological sample that comprises the target nucleic acid. 27. The method according to claim 22, wherein the hybridizing induces a cleavage of the target nucleic acid. 28. The method of claim 22, wherein the target nucleic acid is mRNA. 29. The method of claim 22, wherein the compound cleaves a bond of the target nucleic acid. 30. The method of claim 25, wherein the human or animal subject suffers from a viral infection, bacterial infection, microbial infection, fungal infection, or cancer. 31. A method of inhibiting translation of a nucleic acid in an organism, comprising: predicting or determining a nucleotide sequence of a target nucleic acid in an organism; and administering to the organism a composition according to claim 19, wherein the compound comprises a nucleotide sequence, wherein, under physiological conditions of the organism, said compound is sufficiently complementary to the nucleotide sequence of the target nucleic acid to hybridize thereto in the organism, thereby inhibiting translation of the nucleic acid. 32. The method according to claim 26, wherein the nucleotide sequence of the compound is fully complementary to all or a portion of the nucleotide sequence of the target nucleic acid. 33. A method of making a compound to inhibit translation of a nucleic acid of an organism under physiological conditions of the organism, comprising: a) determining a nucleotide sequence of a target nucleic acid; b) synthesizing a compound that comprises a chelating moiety attached to an oligonucleotide that comprises a nucleotide sequence that is sufficiently complementary to at least part of the nucleotide sequence of the target nucleic acid to permit the hybridization, wherein the oligonucleotide comprises from 5 to 150 nucleobases and wherein at least 10% of the nucleobases of the oligonucleotide are a modified nucleobase selected from the group consisting of: 5-mercaptocytosine, 5-mercaptouracil, 8-mercaptoguanine, 8-mercaptoadenine, 5-hydroxycytosine, 5-hydroxyuracil, 8-hydroxyadenine and 8-hydroxyguanine; and c) mixing said compound with an ion of a metal selected from the group consisting of lanthanum, cerium, praseodymium, neodymium, promethium, samarium, europium, gadolinium, terbium, dysprosium, holmium, erbium, thulium, ytterbium, and lutetium. 34. The method of claim 33, wherein the modified nucleobase is a hydroxynucleobase and is selected from the group consisting of 5-hydroxycytosine, 5-hydroxyuracil, 8-hydroxyadenine and 8-hydroxyguanine. 35. The method of claim 33 wherein the chelating moiety has a formula selected from the group consisting of: wherein R is the oligonucleotide, R1 and R3 are independently selected from the group consisting of hydrogen, C1-8 alkane, C2-8 alkene, C2-8 alkyne, acylC1-8alkane, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, C1-8alkylaryl, and C1-8alkylheteroaryl; and wherein R2 is independently selected from C1-8 alkyl, C2-8 alkene, C2-8 alkyne, aryl, heteroaryl, C1-8alkylaryl, C1-8alkylheteroaryl, and acylC1-8alkane. 36. The method according to claim 33, wherein the conditions comprise human physiological conditions. 37. The compound according to claim 1, wherein the chelating moiety has a formula selected from the group consisting of: wherein R is the oligonucleotide, R1 and R3 are independently selected from the group consisting of hydrogen, C1-8 alkane, C2-8 alkene, C2-8 alkyne, acylC1-8alkane, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, C1-8alkylaryl, and C1-8alkylheteroaryl; and wherein R2 is independently selected from C1-8 alkyl, C2-8 alkene, C2-8 alkyne, aryl, heteroaryl, C1-8alkylaryl, C1-8alkylheteroaryl, and acylC1-8alkane.
연구과제 타임라인
LOADING...
LOADING...
LOADING...
LOADING...
LOADING...
이 특허에 인용된 특허 (199)
Tkachuk Zenovy (Kiev SUX) Kvasyuk Eugeny (Kiev SUX) Matsuka Gennady (Kiev SUX) Mikhailopulo Igor (Kiev SUX), (2′-5′) oligoadenylate analogues useful as inhibitors of host-v5.-graft response.
Huynh Dinh Tam (Croissy/Seine FRX) Gouyette Catherine (Vanves FRX) Igolen Jean (Le Mesnil St. Denis FRX), 2,N6-disubstituted and 2,N6-trisubstituted adenosine-3′-phosphoramidites.
Cook Philip D. (Carlsbad CA) Delecki Daniel J. (Radnor PA) Guinosso Charles (Vista CA), Acyclic nucleoside analogs and oligonucleotide sequences containing them.
Summerton James E. (Corvallis OR) Weller Dwight D. (Corvallis OR) Stirchak Eugene P. (Corvallis OR), Alpha-morpholino ribonucleoside derivatives and polymers thereof.
Miraglia Loren ; Bennett C. Frank ; Dean Nicholas ; Geiger Thomas,DEX, Antisense compositions and methods for modulating type I interleukin-1 receptor expression.
Cook Phillip D. (Carlsbad CA) Sanghvi Yogesh S. (San Marcos CA) Vasseur Jean J. (San Marcos CA) Debart Francoise (Montpellier FRX), Backbone modified oligonucleotide analogues.
Sanghvi Yogesh S. (San Marcos CA) Cook Phillip D. (Vista CA), Backbone-modified oligonucleotide analogs and preparation thereof through radical coupling.
Spielvogel Bernard F. (Raleigh NC) Sood Anup (Durham NC) Hall Iris H. (Chapel Hill NC) Ramsay Shaw Barbara (Durham NC), Boronated nucleoside, nucleotide and oligonucleotide compounds, compositions and methods for using same.
Altmann Karl-Heinz (Basel CHX) Imwinkelried Rene (Brig-Glis CHX) Eschenmoser Albert (Kusnacht CHX), Carbocyclic nucleosides containing bicyclic rings, oligonucleotides therefrom, process for their preparation, their use.
Altmann Karl-Heinz (Basel CHX) Imwinkelried Rene (Brig-Glis CHX) Eschenmoser Albert (Kusnacht CHX), Carbocyclic nucleosides containing bicyclic rings, oligonucleotides therefrom, process for their preparation, their use.
Felgner Philip L. (Rancho Santa Fe CA) Kumar Raj (San Diego CA) Basava Channa (San Diego CA) Border Richard C. (Poway CA) Hwang-Felgner Jiin-Yu (Rancho Santa Fe CA), Cationic lipids for intracellular delivery of biologically active molecules.
Bertsch-Frank Birgit (Rheinfelden DEX) Klasen Claas-Juergen (Freigericht DEX) Lieser Thomas (Hapau DEX) Mueller Klaus (Hasselroth DEX) Bewersdorf Martin (Gelnhausen DEX), Coated sodium percarbonate particles, a process for their production and detergent, cleaning and bleaching compositions.
Curiel David T. (Chapel Hill NC) Birnstiel Max L. (Vienna ATX) Cotten Matthew (Vienna ATX) Wagner Ernst (Langenzersdorf ATX) Zatloukal Kurt (Vienna ATX) Plank Christian (Vienna ATX) Oberhauser Berndt, Composition for introducing nucleic acid complexes into higher eucaryotic cells.
Curiel David T. (Chapel Hill NC) Hu Ping-chuan (Chapel Hill NC) Birnstiel Max L. (Vienna ATX) Cotten Matthew (Vienna ATX) Wagner Ernst (Langenzersdorf ATX), Conjugates for introducing nucleic acid into higher eucaryotic cells.
Smith Lloyd M. (South Pasadena CA) Fung Steven (Palo Alto CA) Kaiser ; Jr. Robert J. (Glendale CA), DNA-reporter conjugates linked via the 2′or 5′-primary amino group of the 5′-terminal nucleoside.
Baxter Anthony D. (Northwich GB2) Baylis Eric K. (Stockport GB2) Collingwood Stephen P. (Westhoughton GB2) Taylor Roger J. (Stretford GB2) De Mesmaeker Alain (Kanerkinden CHX) Schmit Chantal (Basel C, Dinucleoside phosphinates and their pharmaceutical compositions.
Froehler Brian (Belmont CA) Matteucci Mark (Burlingame CA), Enhanced triple-helix and double-helix formation with oligomers containing modified purines.
Froehler Brian (Belmont CA) Wagner Rick (Belmont CA) Matteucci Mark (Burlingame CA) Jones Robert J. (Millbrae CA) Gutierrez Arnold J. (Sandy Lane CA) Pudlo Jeff (Burlingame CA), Enhanced triple-helix and double-helix formation with oligomers containing modified pyrimidines.
Weis Alexander L. (Berwyn PA) Oakes Fred T. (Rochester NY) Hausheer Frederick H. (San Antonio TX) Cavanaugh ; Jr. Paul F. (West Chester PA) Moskwa Patricia S. (Phoenixville PA), Exonuclease resistant terminally substituted oligonucleotides.
Haner Robert,CHX ; Hall Jonathan,CHX ; Husken Dieter,DEX ; Pieles Uwe,DEX ; Moser Heinz,GBX, Functional terpyridine-metal complexes, a process for the preparation thereof and oligonucleotide conjugates with terpy.
Rogers Thomas E. (Manchester MO) Gray Steven H. (Ellisville MO) Devadas Balekudru (Chesterfield MO) Adams Steven P. (St. Charles MO), Improved probes using nucleosides containing 3-dezauracil analogs.
Cohen Jack S. (Bethesda MD) Neckers Len (Bethesda MD) Stein Cy (Gaithersburg MD) Loke She L. (Wheaton MD) Shinozuka Kazuo (Kazo JPX), Inhibitors for replication of retroviruses and for the expression of oncogene products.
Cohen Jack S. (Bethesda MD) Neckers Len (Bethesda MD) Stein Cy (Gaithersburg MD) Loke She L. (Wheaton MD) Shinozuka Kazuo (Kazo JPX), Inhibitors for replication of retroviruses and for the expression of oncogene products.
Cohen Jack S. (Bethesda MD) Neckers Len (Bethesda MD) Stein Cy (Gaithersburg MD) Loke Shee L. (Wheaton MD) Shinozuka Kazuo (Kazo JPX), Inhibitors for replication of retroviruses and for the expression of oncogene products.
Coassin Peter J. (San Juan Capistrano CA) Konrad Kenneth D. (Long Beach CA) Rampal Jang B. (Yorba Linda CA) Cook Ronald M. (San Rafael CA), Inverse linkage oligonucleotides for chemical and enzymatic processes.
Zalipsky Samuel (Fremont CA) Woodle Martin C. (Menlo Park CA) Lasic Danilo D. (Newark CA) Martin Francis J. (San Francisco CA), Lipid-polymer conjugates and liposomes.
Tari Ana Maria (Houston TX) Lopez-Berestein Gabriel (Houston TX) Deisseroth Albert B. (Houston TX), Liposomal antisense methyl phosphonate oligonucleotides and methods for their preparation and use.
Bally Marcel B. (Bowen Island CAX) Boman Nancy L. (Richmond CAX) Cullis Pieter R. (Vancouver CAX) Mayer Lawrence D. (North Vancouver CAX), Liposomal compositions for enhanced retention of bioactive agents.
Hardee Gregory E. ; Geary Richard S. ; Levin Arthur ; Templin Michael V. ; Howard Randy ; Mehta Rahul C., Liposomal oligonucleotide compositions for modulating RAS gene expression.
Woodle Martin C. (Menlo Park CA) Martin Francis J. (San Francisco CA) Yau-Young Annie (Los Altos CA) Redemann Carl T. (Walnut Creek CA), Liposomes with enhanced circulation time.
Low Philip S. (West Lafayette IN) Horn Mark A. (West Lafayette IN) Heinstein Peter F. (West Lafayette IN), Method for enhanced transmembrane transport of exogenous molecules.
Low Philip S. (West Lafayette IN) Horn Mark A. (West Lafayette IN) Heinstein Peter F. (West Lafayette IN), Method for enhancing transmembrane transport of exogenous molecules.
Benner Steven A. (Hadlaubstrasse 151 CH-8006 Zurich CHX), Method for incorporating into a DNA or RNA oligonucleotide using nucleotides bearing heterocyclic bases.
Magda Darren (Cupertino CA) Sessler Jonathan L. (Austin TX) Iverson Brent L. (Austin TX) Sansom Petra I. (Austin TX) Crofts Shaun P. (Campbell CA), Method of expanded porphyrin-oligonucleotide conjugate synthesis.
Unger Evan C. (Tucson AZ) Fritz Thomas A. (Tucson AZ) Matsunaga Terry (Tucson AZ) Ramaswami VaradaRajan (Tucson AZ) Yellowhair David (Tucson AZ) Wu Guanli (Tucson AZ), Methods of preparing gas-filled liposomes.
Froehler Brian ; Wagner Rick ; Matteucci Mark ; Jones Robert J. ; Gutierrez Arnold J. ; Pudlo Jeff, Methods of using oligomers containing modified pyrimidines.
Matteucci Mark (Burlingame CA) Jones Robert J. (Daly City CA) Munger John (San Francisco CA), Modified internucleoside linkages having one nitrogen and two carbon atoms.
Lin Kuei-Ying (Fremont CA) Matteucci Mark (Burlingame CA), Non-nucleoside linkers for convenient attachment of labels to oligonucleotides using standard synthetic methods.
Shizuya Hiroaki (1632 Indiana Ave. South Pasadena CA 91030) Millar Sharon L. (1825 Lanai St. West Covina CA 91792), Non-radioisotope tagging of fragments.
Ts\o Paul O. P. (2117 Folkstone Rd. Lutherville MD 21093) Miller Paul S. (225 Hopkins Rd. Baltimore MD 21212), Nonionic nucleic acid alkyl and aryl phosphonates and processes for manufacture and use thereof.
Nguyen Thanh T. (Tigy FRX) Helene Claude (Saint Cyr en Val FRX) Asseline Ulysse (La Source FRX), Novel compounds containing an oligonucleotide sequence bonded to an intercalating agent, a process for their synthesis a.
Weis Alexander L. (Berwyn PA) Oakes Fred T. (Rochester NY) Hausheer Frederick H. (San Antonio TX) Cavanaugh ; Jr. Paul F. (West Chester PA) Moskwa Patricia S. (Phoenixville PA), Nuclease resistant compounds.
Cook Philip D. (Carlsbad CA) Sanghvi Yogesh S. (San Marcos CA), Nuclease resistant, pyrimidine modified oligonucleotides that detect and modulate gene expression.
Swaminathan Sundaramoorthi ; Matteucci Mark ; Jones Robert J. ; Pudlo Jeff ; Munger John, Nuclease stable and binding competent oligomers and methods for their use.
Buhr Chris (Daly City CA) Matteucci Mark (Burlingame CA) Bischofberger Norbert W. (San Carlos CA) Froehler Brian (Belmont CA), Nucleoside 5′-methylene phosphonates.
Froehler Brian C. (Belmont CA) Buhr Chris A. (Daly City CA), Nucleoside hydrogen phosphonodithioate diesters and activated phosphonodithioate analogues.
Klevan Leonard (Washington DC) Gebeyehu Gulilat (Silver Spring MD) Rao Prasad Y. (Damascus MD), Nucleotide analogs for nucleic acid labeling and detection.
Meyer ; Jr. Rich B. (Woodinville WA) Adams A. David (Snohomish WA) Petrie Charles R. (Woodinville WA), Oligo (aa
상세보기
Letsinger Robert L. (Wilmette IL) Gryaznov Sergei M. (San Mateo CA), Oligodeoxyribonucleotides including 3′-aminonucleoside-phosphoramidate linkages and terminal 3′-amino groups.
Bischofberger Norbert (San Carlos CA) Kent Ken (Mountain View CA) Wagner Rick (Burlingame CA) Buhr Chris (Daly City CA) Lin Kuei-Ying (Fremont CA), Oligonucleotide analogs capable of passive cell membrane permeation.
Weis Alexander Ludvik (Berwyn PA) Hausheer Frederick Herman (San Antonio TX) Chaturvedula Prasad Venkata Chala (Exton PA) Delecki Daniel Joseph (Radnor PA) Cavanaugh ; Jr. Paul Francis (West Chester , Oligonucleotide analogues containing phosphate diester linkage substitutes, compositions thereof, and precursor dinucleo.
Warren ; III Harold C. (Rush NY) Oakes Fred T. (Rochester NY), Oligonucleotide-enzyme conjugate that can be used as a probe in hybridization assays and polymerase chain reaction proce.
Haralambidis Jim (Box Hill South AUX) Tregear Geoffrey W. (Hawthorn AUX), Oligonucleotide-polyamide conjugates and methods of production and applications of the same.
Meyer ; Jr. Rich B. ; Afonina Irina A. ; Kutyavin Igor V., Oligonucleotides containing pyrazolo[3,4-D]pyrimidines for hybridization and mismatch discrimination.
Smith Lloyd M. (South Pasadena CA) Fung Steven (Palo Alto CA) Kaiser ; Jr. Robert J. (Glendale CA), Oligonucleotides possessing a primary amino group in the terminal nucleotide.
Lebleu Bernard (Montpellier FRX) Bayard Bernard (Castelnau Le Lez FRX), Oligonucleotides with modified phosphate and modified carbohydrate moieties at the respective chain termini.
Imbach Jean-Louis (Montpellier FRX) Gosselin Gilles J. M. (Montpellier FRX), Oligonucleotides, a process for preparing the same and their application as mediators of the action of interferon.
Spielvogel Bernard F. (Raleigh NC) Sood Anup (Durham NC) Hall Iris H. (Chapel Hill NC) Shaw Barbara R. (Durham NC), Oligoribonucleoside and oligodeoxyribonucleoside boranophosphates.
Meyer ; Jr. Rich B. (Woodinville WA) Gall Alexander A. (Bothell WA) Reed Michael W. (Seattle WA), Peptide linkers for improved oligonucleotide delivery.
Misiura Konrad (Lodz PLX) Gait Michael (Cambridge GB3), Phosphoramidite derivatives, their preparation and the use thereof in the incorporation of reporter groups on synthetic.
Maddry Joseph A. (Birmingham AL) Reynolds Robert C. (Birmingham AL) Secrist John A. (Birmingham AL) Montgomery John A. (Birmingham AL) Crooks Peter A. (Lexington KY), Polynucleotide analogs containing sulfonate and sulfonamide internucleoside linkages.
Caruthers Marvin H. (Boulder CO) Marshall William S. (Boulder CO) Brill Wolfgang (Freiburg DEX) Nielsen John (Horsholm DKX), Polynucleotide phosphorodithioate.
Urdea Michael S. (Alamo CA) Horn Thomas (Berkeley CA), Polynucleotide reagents containing modified deoxyribose moieties, and associated methods of synthesis and use.
Hawkins Mary E. (Potomac MD) Pfleiderer Wolfgang (Konstanz MD DEX) Davis Michael D. (Rockville MD) Balis Frank (Bethesda MD), Pteridine nucleotide analogs as fluorescent DNA probes.
Van Ness Jeffrey (Bothell WA) Petrie Charles R. (Woodinville WA) Tabone John C. (Bothell WA) Vermeulen Nicolaas M. J. (Woodinville WA), Solid supports for nucleic acid hybridization assays.
Martin Francis J. (San Francisco CA) Woodle Martin C. (Menlo Park CA) Redemann Carl (Walnut Creek CA) Yau-Young Annie (Palo Alto CA), Solid tumor treatment method and composition.
Gordon Julian (307 E. Sheridan Rd. Lake Bluft IL 60044) Minks Michael A. (Biochemistry Dept. ; University of the Witwatersrand ; 1 Jan Smuts Ave Johannesburg 2001 ZAX), Specific antibody to the native form of 2′5′-oligonucleotides, the method of preparation and the use as reagents in im.
Cook Phillip Dan (Carlsbad CA) Manoharan Muthiah (Carlsbad CA) Ramasamy Kanda S. (Laguna Hills CA), Substituted purines and oligonucleotide cross-linking.
Sessler Jonathan L. (Austin TX) Mody Tarak D. (Sunnyvale CA) Hemmi Gregory W. (Sunnyvale CA), Texaphyrin metal complexes having improved functionalization.
Sessler Jonathan L. (Austin TX) Mody Tarak D. (Sunnyvale CA) Hemmi Gregory W. (Sunnyvale CA) Kral Vladimir A. (Austin TX) Magda Darren (Cupertino CA), Texaphyrin-oligonucleotide conjugates.
Unger Evan C. (Tucson AZ) Fritz Thomas A. (Tucson AZ) Matsunaga Terry (Tucson AZ) Ramaswami VaradaRajan (Tucson AZ) Yellowhair David (Tucson AZ) Wu Guanli (Tucson AZ), Therapeutic drug delivery systems.
Reed Michael W. (3575 NE. 180th Seattle WA 98105) Meyer ; Jr. Rich B. (15411 NE. 176th Pl. Woodinville WA 98072), Trifunctional intermediates for preparing 3′-tailed oligonucleotides.
Summerton James E. (Corvallis OR) Weller Dwight D. (Corvallis OR), Uncharged morpolino-based polymers having phosphorous containing chiral intersubunit linkages.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.